Riga, undefined

Avgust Karlovich Aren


Average Co-Inventor Count = 4.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1976-1978

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Avgust Karlovich Aren: A Pioneer in Antiepileptic Compounds

Introduction

Avgust Karlovich Aren is a notable inventor from Riga, SU, recognized for his contributions to the field of chemistry, particularly in the development of antiepileptic compounds. With a total of 2 patents to his name, Aren has made significant strides in the synthesis of innovative chemical compounds.

Latest Patents

Aren's latest patents include the invention of 1-amino-1-phthalidyl alkanes, which are characterized by the formula: ##STR1## where X can be H or CH₃O. This invention focuses on the synthesis of these compounds, which have potential applications in various chemical processes. Another significant patent involves the methylamino derivative of 2-ethylindandione-1,3, which presents antiepileptic compounds of the formula: ##EQU1## where R can be --NHCH₃, --NHC₂H₅, and includes the hydrochlorides thereof. These inventions highlight Aren's commitment to advancing medical chemistry.

Career Highlights

Throughout his career, Avgust Karlovich Aren has worked with various institutions, including the Institut Organicheskogo Sinteza, where he honed his skills in organic synthesis and chemical innovation. His work has contributed to the understanding and development of new therapeutic agents.

Collaborations

Aren has collaborated with notable individuals in his field, including Irma Arnoldovna Berzinya and Ivars Petrovich Lentsbergs. These collaborations have enriched his research and expanded the impact of his inventions.

Conclusion

Avgust Karlovich Aren's contributions to the field of chemistry, particularly in the development of antiepileptic compounds, demonstrate his innovative spirit and dedication to advancing scientific knowledge. His patents reflect a significant impact on the medical and chemical communities.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…